Post-market surveillance continues to show low observed complication rates with OssDsign Cranial PSI
Uppsala, December 16, 2022. OssDsign AB (publ.) today announces updated complaints data from a long-term follow-up of the company's innovative product OssDsign Cranial PSI, which is used in the treatment of cranial bone defects. The data, based on 1,995 surgeries, shows that the frequency of infections leading to implant removal was 1.4% after an average follow-up time of 21 months. This positive outcome exceeds what has been observed in previous follow-ups, thus highlighting the exceptional performance of OssDsign Cranial PSI."The new data from the long-term post-market surveillance study